Castle Biosciences presents new DecisionDx-Melanoma data at SDPA and Dermato-Onco2026 events

Castle Biosciences presents new DecisionDx-Melanoma data at SDPA and Dermato-Onco2026 events
Castle unveils new melanoma data

Castle Biosciences has announced new data regarding its DecisionDx-Melanoma test, which will be presented at two major upcoming industry gatherings. The company will share the findings at the Society of Dermatology Physician Associates (SDPA) 24th Annual Fall Dermatology Conference, taking place from November 11 to 15, 2026 in Hollywood, Florida, as well as at the 3rd European Congress on Dermato-Oncology (Dermato-Onco2026).

These events are significant forums for introducing clinical innovations to industry professionals in dermatology and oncology.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.